据国家药监局官网7月18日消息，流感抗病毒口服药物玛硒洛沙韦片（商品名：济可舒）获批上市，用于治疗既往健康的成人单纯性甲型和乙型流感患者，不包括存在流感相关并发症高风险的患者。

Core Viewpoint - The approval of the antiviral oral medication, Marselevavir tablets (brand name: Jikeshou), by the National Medical Products Administration marks a significant development in the treatment of influenza for previously healthy adults with uncomplicated type A and B influenza [1] Group 1 - The medication is specifically indicated for treating uncomplicated influenza in previously healthy adults, excluding patients at high risk for flu-related complications [1]